Back to Newsroom

DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

LONDON, Nov. 10, 2016 /PRNewswire/ — DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC, will present data at the American Heart Association Scientific Sessions 2016 (AHA) during the Abstract Rapid Fire Session on Sunday, November 13, 2016 in New Orleans.

The data presented further dissects the mechanism of genotype-dependent benefits of dalcetrapib on atherosclerotic cardiovascular outcomes, high-sensitivity C-reactive protein (hs-CRP) and cholesterol efflux in patients with the AA genotype at polymorphism rs1967309 of the ADCY9 gene.

Click here to read the full release